Working… Menu
Trial record 1 of 201 for:    Venetoclax
Previous Study | Return to List | Next Study

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03639324
Recruitment Status : Not yet recruiting
First Posted : August 21, 2018
Last Update Posted : October 16, 2019
Information provided by (Responsible Party):
Virginia Commonwealth University

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : March 30, 2022
Estimated Study Completion Date : September 30, 2025